N-Acetyl-Cysteine (NAC) has been described as a PPARα agonist, which inhibits the proliferation of non-small-cell lung carcinoma cells through the induction of p53 and the inhibition of p65, collaboratively reducing PDK1 promoter activity and expression [279]. Here, PPARA is linked to non-small cell lung carcinoma.